NCT01627132

Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial

Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Shimousa Hematology Study Group · Academic / Other
• Sex: All
• Age: 15 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess whether dasatinib can be discontinued without occurrence of molecular relapse in patients with chronic myeloid leukemia in chronic phase in complete molecular remission (CMR) while on dasatinib.

Conditions

• Chronic Myeloid Leukemia

Interventions

Type	Name	Description
DRUG	Dasatinib	100mg QD

Timeline

• Start date: 2012-02-01
• Primary completion: 2017-02-01
• Completion: 2019-01-01
• First posted: 2012-06-25
• Last updated: 2012-06-25

Locations

1 site across 1 country: Japan